• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
HU Yue, CHEN Zhou, LUO Xiaoxing, XUE Xiaoyan. Research progress of 1, 2-dilinoleyloxy-3-dimethylaminopropane-based cationic lipid nanoparticle[J]. Journal of China Pharmaceutical University, 2016, 47(1): 112-117. DOI: 10.11665/j.issn.1000-5048.20160117
Citation: HU Yue, CHEN Zhou, LUO Xiaoxing, XUE Xiaoyan. Research progress of 1, 2-dilinoleyloxy-3-dimethylaminopropane-based cationic lipid nanoparticle[J]. Journal of China Pharmaceutical University, 2016, 47(1): 112-117. DOI: 10.11665/j.issn.1000-5048.20160117
shu

Research progress of 1, 2-dilinoleyloxy-3-dimethylaminopropane-based cationic lipid nanoparticle

More Information
    Graphical Abstract
    • Abstract
  • Cationic lipid nanoparticles possessing favorable biocompatibility and controllable particle size have attracted increasing attention in the field of non-viral vectors for delivering nucleic acids in vitro and in vivo. 1, 2-Dilinoleyloxy-3-dimethylaminopropane(DLinDMA)and its derivatives, one kind of most important cationic lipid materials, have been widely studied as the main composition of cationic lipid nanoparticles. This paper summarizes the structure, characteristics and clinical application of DLinDMA nanoparticles.
    • FullText(HTML)
    • References (15)
  • [1]
    Bai H.Design,synthesis and antibacterial activity of antisense peptide nucleic acid targeting bacterial RNA polymerase primary σ70[D].Xi′an:the Fourth Military Medical University,2011.
    [2]
    Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates[J].Nature,2006,441(7089):111-114.
    [3]
    Semple SC,Akinc A,Chen J,et al.Rational design of cationic lipids for siRNA delivery[J].Nat Biotechnol,2010,28(2):172-176.
    [4]
    Miller AD.Delivery of RNAi therapeutics:work in progress[J].Expert Rev Med Devices,2013,10(6):781-811.
    [5]
    Zhou YD,Li J.Cationic liposome used as gene vector:materials and preparation techniques[J].Prog Pharm Sci(药学进展),2009,33(7):297-304.
    [6]
    Kanasty R, Dorkin JR, Vegas A, et al. Delivery materials for siRNA therapeutics[J].Nat Mater,2013,12(11):967-977.
    [7]
    Miller AD.Delivering the promise of small ncRNA therapeutics[J].Ther Deliv,2014, 5(5):569-589.
    [8]
    Kolli S,Wong SP,Harbottle R,et al.pH-triggered nanoparticle mediated delivery of siRNA to liver cells in vitro and in vivo[J].Bioconjug Chem,2013, 24(3):314-332.
    [9]
    Kenny GD,Kamaly N,Kalber TL,et al.Novel multifunctional nanoparticle mediates siRNA tumour delivery,visualisation and therapeutic tumour reduction in vivo[J].J Control Release,2011, 149(2):111-116.
    [10]
    Medina-Kauwe LK,Xie J,Hamm-Alvarez S.Intracellular trafficking of nonviral vectors[J].Gene Ther,2005, 12(24):1734-1751.
    [11]
    Kang MR,Yang G,Place RF,et al.Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth[J].Cancer Res,2012, 72(19):5069-5079.
    [12]
    Guo J,Cahill MR,McKenna SL,et al.Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia[J].Biotechnol Adv,2014, 32(8):1396-1409.
    [13]
    Kajimoto K,Sato Y,Nakamura T,et al.Multifunctional envelope-type nano device for controlled intracellular trafficking and selective targeting in vivo[J].J Control Release,2014,190:593-606.
    [14]
    Haynes M,Huang L.Hepatic RNA interference:delivery by synthetic vectors[J].Drug Deliv Transl Res,2014,4(1):61-73.
    [15]
    Hobo W,Novobrantseva TI,Fredrix H,et al.Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation[J].Cancer Immunol Immunother,2013, 62(2):285-297.
    • Related Articles

  • Related Articles

    [1]REN Yanwei, LI Qiyi, HE Bing, LI Haoyu, ZHAO Li, LI Yuyan. Research progress of enzyme-instructed self-assembly molecules for tumor therapy and imaging[J]. Journal of China Pharmaceutical University, 2023, 54(4): 431-442. DOI: 10.11665/j.issn.1000-5048.2023020602
    [2]LU Zhipeng, XU Qinglong, CHEN Panpan, QIN Yajuan, TANG Lijun, LI Tingyou. Research progress of radioprobes targeting fibroblast activating protein[J]. Journal of China Pharmaceutical University, 2022, 53(6): 651-662. DOI: 10.11665/j.issn.1000-5048.20220603
    [3]WANG Rui, ZHOU Xinjie, DU Xiqin, HAO Di, WANG Chen, ZOU Bingjie, SONG Qinxin, ZHOU Guohua. Research progress of next-generation gene editing tools[J]. Journal of China Pharmaceutical University, 2022, 53(6): 633-642. DOI: 10.11665/j.issn.1000-5048.20220601
    [4]YANG Wanwan, YE Fangyu, WU Yujia, WANG Haochen, ZHAO Li. Research progress of PARP inhibitors in cancers and their drug resistance[J]. Journal of China Pharmaceutical University, 2022, 53(5): 525-534. DOI: 10.11665/j.issn.1000-5048.20220503
    [5]WANG Zhenghao, GAO Yafeng, ZHANG Lianjun, LIU Chang. Research progress of T cell anti-tumor function regulated by endoplasmic reticulum stress[J]. Journal of China Pharmaceutical University, 2022, 53(5): 518-524. DOI: 10.11665/j.issn.1000-5048.20220502
    [6]LIU Li, ZHANG Qianwen, NONG Cheng, ZHANG Xi, XU Xiaoting, Mohammed Ismail, XIAO Li, JIANG Zhenzhou, ZHANG Luyong, SUN Lixin. Research progress of lncRNA regulating signal transduction pathway in liver diseases[J]. Journal of China Pharmaceutical University, 2020, 51(3): 277-286. DOI: 10.11665/j.issn.1000-5048.20200304
    [7]MEI Liankuo, WEI Qiangqiang, ZHANG Huibin, ZHOU Jinpei. Research progress in acetyl-CoA carboxylase inhibitors[J]. Journal of China Pharmaceutical University, 2019, 50(3): 253-264. DOI: 10.11665/j.issn.1000-5048.20190301
    [8]WANG Chen, XU Jun, LIU Yanhua, WANG Zengtao, HU Yue, TIAN Taiping, YI Mengjuan. Research progress on functionalized graphene oxide as drug carriers[J]. Journal of China Pharmaceutical University, 2017, 48(1): 117-124. DOI: 10.11665/j.issn.1000-5048.20170118
    [9]ZHANG Danfeng, JIAO Yu, LIU Yong, ZHANG Yanmin, ZHANG Zhimin, LU Tao. Progress of small molecule anti-tumor covalent drugs[J]. Journal of China Pharmaceutical University, 2017, 48(1): 1-7. DOI: 10.11665/j.issn.1000-5048.20170101
    [10]YAO Aihong, CHANG Yujie, JIANG Cheng, SUN Haiying. Research progress of Polo-like kinase 1 inhibitors targeting Polo-box domain[J]. Journal of China Pharmaceutical University, 2016, 47(1): 1-8. DOI: 10.11665/j.issn.1000-5048.20160101

Catalog

    Get Citation
    PDF
    XML
    Article views (1494) PDF downloads (2218) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：457021

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return